OncoTherapy Science, Inc.
4564.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.57B
Close$
Share Statistics
| Market cap | $7.57 Billion |
|---|---|
| Enterprise Value | $5.25 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.77 |
| Beta | 0.3 |
| Outstanding Shares | 398,821,594 |
Return
| Return on Equity | -37.69% |
|---|---|
| Return on Assets | -33.88% |
| Return on Invested Capital | -37.73% |
Valuation & Multiples
| P/E Ratio | -8.05 |
|---|---|
| PEG | 99.52 |
| Price to Sales | 19.0 |
| Price to Book Ratio | 3.8 |
| Enterprise Value to Revenue | 6.75 |
| Enterprise Value to EBIT | -5.81 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 7, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About OncoTherapy Science, Inc.
46 employees
CEO: Junichi Shimada OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecula...